SCHEMBL19902482

SCHEMBL19902482

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1nc2ccc(Cl)cc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.45
HRH4 Q9H3N8 4/20 0.43
HRH3 Q9Y5N1 2/20 0.43
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 2/20 0.41
PDE10A Q9Y233 1/20 0.41
ROCK2 O75116 1/20 0.40
TNKS O95271 5/20 0.39
PARP2 Q9UGN5 2/20 0.39
CHEK1 O14757 1/20 0.39
HPGD P15428 2/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
KMT2A Q03164 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452817 0.89 ROCK2 (0.52) SMYD3HRH4HRH3LMNAL3MBTL1
SCHEMBL19902484 0.78 CHRNA7 (0.46) L3MBTL1ROCK2MEN1NPC1KMT2A
SCHEMBL19902458 0.77 SCN4A (0.48) SMYD3ROCK2MEN1NPC1KMT2A
SCHEMBL19902711 0.75 PYGL (0.48) SMYD3ROCK2
SCHEMBL19902585 0.74 CHEK1 (0.47) SMYD3LMNAROCK2CHEK1HPGD
SCHEMBL19902631 0.74 HDAC8 (0.42) LMNAROCK2HPGDGAANPC1
SCHEMBL19902689 0.73 ROCK2 (0.46) SMYD3LMNAROCK2MEN1NPC1
SCHEMBL19902625 0.73 MLLT1 (0.49) SMYD3ROCK2MEN1NPC1KMT2A
SCHEMBL19902356 0.73 CHRNA7 (0.45) SMYD3ROCK2NPC1
SCHEMBL19902628 0.73 RIPK1 (0.48) SMYD3HRH4HRH3ROCK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 SMYD3 1799/4885HRH4 4125/4885HRH3 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.